ABUS
Arbutus Biopharma Corp
4.50$
-4.1%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | 584.9% | 553.2% | 535.5% | 1,115.8% | 246.9% | 94.1% | 45.5% | 80.3% | 137.4% | 123.1% | 103.6% | 119.5% | 127.8% | 138.8% | 258.0% | 207.1% | 4,086.7% | 586.0% | 981.4% | 958.3% | 686.7% | 16.0% | 3.7% | 406.3% | 22.4% | 2.6% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 54.5% | 100.0% | -37.4% | -23.1% | -3.6% | -19.5% | -27.8% | -38.8% | -158.0% | -107.1% | -3,986.7% | -486.0% | -881.4% | -858.3% | -586.7% | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% | |
| 704.8% | 679.3% | 493.0% | 371.4% | 426.0% | 867.7% | 183.4% | 65.9% | 33.3% | 52.9% | 137.5% | 122.5% | 103,665,632.5% | 119.7% | 127.8% | 138.8% | 258.0% | 207.1% | 4,086.7% | 586.0% | 981.4% | 958.3% | 713.6% | 596.1% | 216.3% | 406.3% | 875.7% | 179.2% | |
| 108.4% | 137.4% | 127.5% | 89.6% | 108.9% | 248.3% | 63.7% | 28.5% | 28.3% | 27.9% | 37.5% | 28.8% | 22.4% | 37.9% | 189.6% | 35.9% | 58.0% | 106.3% | 2,626.7% | 150.5% | 271.2% | 294.9% | 214.7% | 156.0% | 45.7% | 123.9% | 358.3% | 112.9% | |
| 813.2% | 816.7% | 620.6% | 574.4% | 646.5% | 1,368.1% | 292.1% | 108.2% | 66.9% | 83.4% | 49.1% | 42.7% | 55.0% | 43.8% | -137.4% | 178.6% | 319.3% | 315.7% | 6,786.7% | 755.1% | 1,289.8% | 1,535.7% | 249.3% | 769.1% | 267.8% | 530.5% | 1,336.7% | 289.5% | |
| -713.2% | -716.7% | -520.6% | -474.4% | -546.5% | -1,268.1% | -227.1% | -44.8% | -12.4% | 16.6% | -113.6% | -65.8% | -58.6% | -63.3% | -91.6% | -78.6% | -220.0% | -411.4% | -32,773.3% | -1,036.4% | -1,522.0% | -2,394.0% | -836.1% | -669.1% | -167.8% | -430.5% | -1,236.7% | -192.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 11.8% | 6.4% | 0.0% | 1.1% | 0.5% | 0.5% | 0.3% | 3.5% | 5.7% | 2.7% | 92.7% | 2.4% | 3.4% | 35.1% | 58.0% | 26.0% | 4.4% | 2.5% | 2.2% | 0.7% | |
| – | – | 0.0% | -461.2% | 0.0% | 0.0% | -244.9% | -57.7% | 132.9% | -16.2% | -121.6% | -68.8% | -58.6% | -60.4% | 211.2% | -90.9% | -258.0% | -310.8% | -32,606.7% | -1,015.9% | -1,040.7% | -2,767.9% | -922.0% | -693.9% | -166.6% | -401.6% | -1,133.0% | -237.9% | |
| 0.0% | 0.0% | 0.0% | -67.3% | -16.8% | -17.7% | 73.5% | 2.9% | 0.0% | 0.0% | 35.0% | 1.9% | -0.5% | -3.6% | 26.2% | 12.4% | 0.7% | -65.1% | -7,000.0% | -227.1% | -72.9% | -210.5% | 21.2% | 10.0% | 11.4% | 0.0% | – | – | |
| -713.2% | -716.7% | -520.6% | -405.1% | -528.3% | -1,247.3% | -230.5% | -60.6% | 132.9% | -16.2% | -121.6% | -67.7% | -58.1% | -59.7% | 211.2% | -90.9% | -258.7% | -245.7% | -25,606.7% | -788.8% | -967.8% | -2,557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1,133.0% | -237.9% | |
| -632.6% | -602.3% | -532.4% | -363.5% | -435.0% | -1,016.0% | -147.1% | 9.9% | 154.1% | 19.2% | -75.0% | -48.9% | -51.7% | -55.6% | 241.1% | -74.6% | -216.3% | -308.4% | -32,538.3% | -994.8% | -999.2% | -2,699.1% | -835.3% | -652.0% | -158.5% | -391.3% | -1,108.5% | -234.6% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.